BioPharma Dive - Latest News

Intellia filing spurs safety concerns over CRISPR drug

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study participant given one of its gene editing treatments. 

May 29, 2025 - 17:30
 0
Intellia filing spurs safety concerns over CRISPR drug

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study participant given one of its gene editing treatments. 

Read More

Tags:

Previous Article

HHS terminates Moderna contract to develop bird flu vaccine

Next Article

The D Brief: Cuts to DOT&E; Uncrewed F-35?; Qatari jet’s a mess; Border gets bar...

Related Posts

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

Prime Medicine claims ‘proof of concept,’ but lays off ...

May 19, 2025  0

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume ...

May 22, 2025  0

Lilly to buy pain drug developer SiteOne, challenging Vertex

Lilly to buy pain drug developer SiteOne, challenging V...

May 27, 2025  0